The The Importance of Elevated Basal 17-hydroxyprogesterone in the Diagnosis of Children with Congenital Adrenal Hyperplasia

  • Vera Zdravković UDK Tiršova MFUB
  • Prof University Children's Hospital
  • dr Children's Department of Neonatology, General Hospital "Stefan Visoki", Smederevska Palanka, Serbia
  • Sonja Pavlović Institut za molekularnu genetiku i genetičko inženjerstvo
DOI: https://doi.org/10.5937/jomb0-54426
Keywords: 17-hydroxyprogesterone, congenital adrenal hyperplasia, precocious puberty, CYP21A2 heterozygous, CYP21A2 gene.

Abstract


Introduction: Congenital adrenal hyperplasia (CAH) is characterized by a deficiency of 21α-hydroxylase causing a deficiency of cortisol and aldosterone and overproduction of 17-hydroxyprogesterone. The classic and non-classical forms of the disease present with signs of precocious puberty (PP) and accelerated body and bone growth. Elevated basal and stimulated 17-hydroxyprogesterone and genetic testing are crucial for confirming a definitive diagnosis.

Aim: To determine the significance of elevated basal 17-hydroxyprogesterone in children with signs of precocious puberty in the final diagnosis of Congenital Adrenal Hyperplasia.

Material and methods: A prospective study was conducted at the University Children's Clinic and the Institute of Molecular Genetics and Genetic Engineering in Belgrade from 2019 to 2024. The study involved 64 subjects of both sexes, aged up to 18 years, with precocious puberty, accelerated bone and body growth, elevated basal 17-hydroxyprogesterone, who were divided into two groups based on the presence/absence of pathogenic variants in the CYP21A2 gene. The anthropometric measures, skeletal maturation and hormone levels were compared between those two groups.

Results: The research includes 64 subjects, divided into two groups, with confirmed CAH (30 subjects) and with PP as the control group (34 subjects). A statistically significant difference was shown in basal (p=0.000000807) and stimulated 17-hydroxyprogesterone (p= 0.0125), cortisol (p= 0.0148) and androstenedione (p= 0.014) in homozygous carriers of pathogenic variants in the CYP21A2 gene.

Conclusion: Clinical and laboratory parameters such as precocious puberty and 17-hydroxyprogesterone may be significant hints to consider a carrier mutation for congenital adrenal hyperplasia.

References

1. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018; 103(11):4043-4088.
2. Navarro-Zambrana AN, Sheets LR. Ethnic and National Differences in Congenital Adrenal Hyperplasia Incidence: A Systematic Review and Meta-analysis. Horm Res Paediatr. 2023; 96(3):249-258.
3. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet. 1985; 37(4):650-67.
4. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, et al. Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management. Endocr Rev. 2022; 43(1):91-159.
5. Honour JW. 17-Hydroxyprogesterone in children, adolescents and adults. Ann Clin Biochem. 2014; 51 (Pt 4):424-40.
6. Witchel SF. Congenital Adrenal Hyperplasia. J Pediatr Adolesc Gynecol. 2017; 30 (5):520-534.
7. ) Milacic I, Barac M, Milenkovic T, Ugrin M, Klaassen K, Skakic A, et al. Molecular genetic study of congenital adrenal hyperplasia in Serbia: novel p.Leu129Pro and p.Ser165Pro CYP21A2 gene mutations. J Endocrinol Invest. 2015;38(11):1199-210. doi: 10.1007/s40618-015-0366-8. Epub 2015 Aug 2. PMID: 26233337..(7)
8. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med. 1992; 11(10):1305-19.
9. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976; 51(3):170-9.
10. Held PK, Bird IM, Heather NL. Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy. Int J Neonatal Screen. 2020; 6(3):67.
11. Silva RS, Carvalho B, Pedro J, Castro-Correia C, Carvalho D, Carvalho F, et al. Differences in hormonal levels between heterozygous CYP21A2 pathogenic variant carriers, non-carriers, and females with non-classic congenital hyperplasia. Arch. Endocrinol. Metab. 2022; 66(2):168-75.
12. Bello R, Lebenthal Y, Lazar L, Shalitin S, Tenenbaum A, Phillip M, et al. Basal 17-hydroxyprogesterone cannot accurately predict nonclassical congenital adrenal hyperplasia in children and adolescents. Acta Paediatr. 2017; 106(1):155-160.
13. Kim KW. Unravelling Polycystic Ovary Syndrome and Its Comorbidities. J Obes Metab Syndr. 2021; 30(3):209-221. 
Published
2025/10/13
Issue
Ahead of print
Section
Original paper

Copyright (c) 2025 Vera Zdravković

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.